What is a stock summary page? Click here for an overview.
Business Description
Compare
Compare
Traded in other countries / regions
543635.India Index Membership
NIFTY 500 IPO Date
2022-10-19Description
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.1 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.61 | |||||
| Debt-to-EBITDA | 3.05 | |||||
| Interest Coverage | 1.44 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.11 | |||||
| Beneish M-Score | -2.63 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | 172.18 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 14.06 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 31.82 | |||||
| 9-Day RSI | 42.7 | |||||
| 14-Day RSI | 47.04 | |||||
| 3-1 Month Momentum % | -2.72 | |||||
| 6-1 Month Momentum % | -7.25 | |||||
| 12-1 Month Momentum % | 59.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.03 | |||||
| Quick Ratio | 0.56 | |||||
| Cash Ratio | 0.09 | |||||
| Days Inventory | 226.15 | |||||
| Days Sales Outstanding | 78.12 | |||||
| Days Payable | 146.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.05 | |||||
| Dividend Payout Ratio | 0.32 | |||||
| Forward Dividend Yield % | 0.05 | |||||
| 5-Year Yield-on-Cost % | 0.05 | |||||
| Shareholder Yield % | 1.23 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.53 | |||||
| Operating Margin % | 6.98 | |||||
| Net Margin % | 0.44 | |||||
| FCF Margin % | 3.29 | |||||
| ROE % | 0.49 | |||||
| ROA % | 0.26 | |||||
| ROIC % | 0.5 | |||||
| ROC (Joel Greenblatt) % | 10.8 | |||||
| ROCE % | 7.47 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 656.06 | |||||
| Forward PE Ratio | 61.05 | |||||
| PE Ratio without NRI | 636.76 | |||||
| PS Ratio | 3.18 | |||||
| PB Ratio | 3.61 | |||||
| Price-to-Tangible-Book | 7.66 | |||||
| Price-to-Free-Cash-Flow | 95 | |||||
| Price-to-Operating-Cash-Flow | 27.66 | |||||
| EV-to-EBIT | 41.16 | |||||
| EV-to-EBITDA | 20.97 | |||||
| EV-to-Revenue | 3.71 | |||||
| EV-to-FCF | 112.55 | |||||
| Price-to-Graham-Number | 11.38 | |||||
| Earnings Yield (Greenblatt) % | 2.43 | |||||
| FCF Yield % | 1.02 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Piramal Pharma Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 88,847.2 | ||
| EPS (TTM) (₹) | 0.33 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 39.95 | ||
| 14-Day RSI | 47.04 | ||
| 14-Day ATR (₹) | 7.989422 | ||
| 20-Day SMA (₹) | 220.785 | ||
| 12-1 Month Momentum % | 59.72 | ||
| 52-Week Range (₹) | 136.1 - 307.9 | ||
| Shares Outstanding (Mil) | 1,320.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Piramal Pharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Piramal Pharma Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Piramal Pharma Ltd Frequently Asked Questions
What is Piramal Pharma Ltd(NSE:PPLPHARMA)'s stock price today?
The current price of NSE:PPLPHARMA is ₹216.25. The 52 week high of NSE:PPLPHARMA is ₹307.90 and 52 week low is ₹136.10.
When is next earnings date of Piramal Pharma Ltd(NSE:PPLPHARMA)?
The next earnings date of Piramal Pharma Ltd(NSE:PPLPHARMA) is .
Does Piramal Pharma Ltd(NSE:PPLPHARMA) pay dividends? If so, how much?
The Dividend Yield %  of Piramal Pharma Ltd(NSE:PPLPHARMA) is 0.05% (As of Today), Highest Dividend Payout Ratio of Piramal Pharma Ltd(NSE:PPLPHARMA) was 0.32. The lowest was 0. And the median was 0. The  Forward Dividend Yield % of Piramal Pharma Ltd(NSE:PPLPHARMA) is 0.05%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers